Cancer immunotherapies often rely on activating immune responses, yet many tumors remain resistant because their internal survival mechanisms are poorly understood.

The cGAS-STING signaling pathway has emerged as a major focus in cancer immunotherapy because it stimulates interferon production and enhances antitumor immune responses. However, despite strong ...